ALX Oncology Holdings Inc. set terms of its initial public offering, in which the California-based immuno-oncology company looks to raise up to $136 million and be valued at up to $590.1 million. The company is selling 8 million shares in the IPO, which is expected to price between $15 and $17 a share. There will be 34.71 million shares outstanding after the IPO. Jefferies, Credit Suisse, Piper Sandler and Cantor are the lead underwriters. The company recorded a net loss of $7.4 million on related-party revenue of $655,000 over the three months ended March 31, after a loss of $5.1 million on revenue of $1.0 million in the same period a year ago. The company is looking to go public at a time that the Renaissance IPO ETF has soared 61.7% over the past three months while the S&P 500 has advanced 15.3%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- The number of Americans skipping mortgage payments drops to lowest level since April — but some borrowers face bigger challenges - September 22, 2020
- The Supreme Court’s Obamacare case was high stakes before Ruth Bader Ginsburg’s death. Here’s why it’s even more important now - September 22, 2020
- Scientists examine how adults and children fight off COVID-19 — and say it may have implications for vaccine research - September 22, 2020